neuropeptide y (1336), amide, human

Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.

[D-Trp34]-Neuropeptide Y Acetate is a potent and selective agonist of neuropeptide Y (NPY) Y5 receptor. [D-Trp34]-Neuropeptide acetate Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y Acetate markedly increases food intake in rats.

Neuropeptide Y (scrambled) Acetate (Pro-Neuropeptide Y (scrambled) Acetate) is a scrambled peptide of Neuropeptide Y that has been implicated in Alzheimer's disease (AD) and may have neuroprotective effects.

Neuropeptide SF (human) aceate is a neuropeptide that augmented paraventricular CRH release and increased ACTH and corticosterone levels in the plasma.

Neuropeptide AF (human) acetate (Neuropeptide AF (human) acetate (192387-38-5 Free base)) is an anti-opioid neuropeptide, a Neuropeptide AF (human) derivative, which regulates adipocyte metabolism.

Neuropeptide Y (29-64), amide, human acetate is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

High affinity neuropeptide Y Y1 receptor agonist

Neuropeptide W-23(human) (NPW-23) is an endogenous ligand for NPBW1 and NPBW2.

Neuropeptide Y (NPY) (3-36) is a C-terminal fragment of NPY, a neuropeptide involved in controlling appetite, blood pressure, cardiac contractility, and intestinal secretion. NPY (3-36) is an endogenous peptide produced by cleavage of NPY by dipeptidyl peptidase 4 (DPP-4). It binds selectively to the NPY receptor Y2 (Ki = 0.41 nM in CHP 234 cells) over the Y1 receptor, where it does not bind at concentrations up to 1 μM. NPY (3-36) (0.1 nM) increases migration of human umbilical vein endothelial cells (HUVECs) by 80% after 12 hours in an in vitro wound closure assay. NPY (3-36) corresponds to residues 3-36 of the human and rat protein sequence.

Neuropeptide Y (1-24) (human) is a neuropeptide that inhibits electrically stimulated twitch responses in rat vas deferens and activates neurons in the rat CA3 region of the dorsal hippocampus in vivo following N-methyl-D-aspartate (NMDA) induction [1] [2].

Neuropeptide Y(29-64) is a 36-amino acid peptide fragment of Neuropeptide Y.

[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY), a Y1 receptor selective agonist, is involved in Alzheimer's disease (AD) and protects rat cortical neurons from β-Amyloid toxicity [1].

Gastric Inhibitory Polypeptide (6-30) amide (human) is an incretin hormone used in diabetes research [1].

'(Des-Bromo)-Neuropeptide B (1-23) (human)' is an agonist for orphan G-protein-coupled receptors, exhibiting a K i of 1.2 nM for GPR7 (NPBW1) and 341 nM for GPR8 (NPBW2) respectively [1].

Neuropeptide Y (29-64), amide, human is a biologically active 36-amino acid peptide.

Neuropeptide Y (18-36) (porcine) acts as a competitive antagonist of the neuropeptide Y (NPY) cardiac receptor, blocking I-NPY attachment to cardiac ventricular membranes. Its concentration-dependent action has an IC50 value of 158 nM and a Ki value of 140 nM. This compound is utilized in studying congestive heart failure [1].

Neuropeptide Y (22-36), a 15-amino-acid peptide, is a fragment of Neuropeptide Y (NPY), a 36-amino-acid neuropeptide involved in various physiological and homeostatic processes in the central and peripheral nervous systems. NPY, the most abundant peptide in the mammalian central nervous system, is secreted alongside neurotransmitters such as GABA and glutamate.

Neuropeptide Y (3-36) (human, rat) is a metabolite of neuropeptide Y (NPY) generated by dipeptidyl peptidase-4 (DPP4) and is known as a selective Y2 receptor agonist, effectively reducing the release of norepinephrine via the Y2 receptor [1][2].

Neuropeptide S human (TFA) is a potent endogenous neuropeptide S receptor agonist (EC50=9.4 nM).

GLP-1 (1-36) amide (human, rat) TFA, a variant of GLP-1 (7-36) amide, induces [14C]aminopyrine accumulation in enzymatically dispersed enriched rat parietal cells [1].

Neuropeptide Y (2-36) (porcine) is a pig-sourced peptide closely resembling its rat and human counterparts with 97.14% homology. It acts as an agonist for rat neuropeptide receptors Y5, Y2, and Y1, with EC50 values of 1.2, 1.6, and 3.4 nM, respectively. This compound is utilized in research on obesity and eating disorders [1].

Potent neuropeptide Y (NPY) Y5 receptor agonist (pEC50 values are 7.82, 6.28, 6.44 and > 6 at rat Y5, Y4, Y1 and Y2 receptors respectively) that displays > 26-fold, > 1000-fold and > 1000-fold selectivity over Y1, Y2 and Y4 receptors respectively. Induces

Mca-(endo-1a-Dap(Dnp))-TNF-Alpha (-5 to +6) amide (human) is a peptide used as a fluorescence resonance energy transfer (FRET) based substrate for proteolytic activity assays, with cleavage-induced changes in fluorescence intensity indicating enzymatic activity [1].

Biotinyl-neuropeptide W-23 (human) is a biotinylated variant of neuropeptide W-23 (human) that acts as an agonist for the NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1] [2].

(D-Ala2)-GRF (1-29) amide (human) is a potent superagonist of Growth Hormone-Releasing Factor (GRF), exhibiting approximately 50-fold higher GH-releasing activity than GRF (1-29) in both pigs and rats [1].

PTH-Related Protein (7-34) amide (human, mouse, rat) serves as a potent antagonist of parathyroid hormone (PTH) [1].

Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat), also known as Human PTHrP (107-111) amide, is a C-terminal fragment of parathyroid hormone-related protein that inhibits bone resorption [1][2].

GLP-1 (1-36) amide (human, rat) is a molecular variant of the GLP-1 (7-36) amide and has the capacity to stimulate [14C]aminopyrine accumulation in enzymatically dispersed, enriched rat parietal cells [1].

Galanin (2-11) amide is a synthetic peptide fragment of the neuropeptide galanin and an agonist of the galanin-2 (GAL2) receptor (EC50= 9.32 nM in a fluorescence imaging plate reader assay).1It selectively binds to the GAL2receptor (IC50= 1.76 nM for the rat receptor) over the GAL1receptor (IC50= 879 nM for the human receptor) but does also bind to the GAL3receptor (Ki= 271 nM for the rat receptor).1,2Intracerebroventricular administration of galanin (2-11) amide (1 nmol/animal) decreases immobility in the forced swim test in rats.3It also reduces the hind paw mechanical pain threshold and increases the hind paw cold sensitivity threshold in rats.1

(Ser8)-GLP-1 (7-36) amide, human, is a glucagon-like peptide-1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. This entero-insulinotropic hormone promotes glucose-dependent insulin secretion from pancreatic β-cells and affects gastrointestinal motility and secretion [1].

[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) is an analog of GRF and a vasoactive intestinal peptide (VIP) antagonist.

GIP (1-30) amide, human acetate is a fragment of glucose-dependent insulinotropic polypeptide (GIP), an incretin hormone that plays a crucial role in stimulating insulin secretion and mitigating postprandial glycemic excursions. This compound has been shown to enhance insulin secretion in a dose-dependent manner across concentrations of 10^-9 to 10^-6 M [1].

Agouti-related Protein (AGRP) (83-132) Amide (human) is a segment derived from the agouti-related protein (AGRP), abundantly present in the hypothalamus' arcuate nucleus, and functions predominantly as an inverse agonist for the melanocortin-4 receptor (MC4R), thereby promoting food intake [1] [2].

Neuropeptide Y (porcine), a peptide found in the porcine brain, effectively inhibits secretin-stimulated pancreatic secretion [1].

[D-Trp34]-Neuropeptide Y TFA is a potent and selective agonist for the neuropeptide Y (NPY) Y5 receptor, demonstrating significantly lower potency at the NPY Y1, Y2, Y4, and Y6 receptors. It significantly increases food intake in rats [1] [2].

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide biotinylated at the C-terminal.

[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA acts as a specific agonist for the neuropeptide Y Y1 receptor and also activates Y4 and Y5 receptors, elevating blood pressure in anesthetized rats and enhancing food intake [1] [2].

Neuropeptide Y (NPY) is a 36-amino acid neuropeptide that exerts its activity via G-protein-coupled receptors. NPY is widely distributed in the peripheral and central nervous systems. It modulates a variety of physiological processes, e.g. the central reg

(Asn10,Leu11,D-Trp12)-pTH-Related Protein (7-34) amide (human, mouse, rat) is a potent antagonist of the PTH-1R [1][2].

Somatorelin (1-44) amide is a synthetic peptide that corresponds to the full 44-amino acid sequence of growth hormone-releasing hormone (GHRH), a hormone that stimulates the production of growth hormone from the pituitary gland and is involved in the regulation of cell proliferation and differentiation.1,2Somatorelin induces growth hormone release similarly to GHRHin vitroandin vivo.1

Neuropeptide Y (NPY), a neuropeptide, plays roles in regulating appetite, vasoconstriction, cardiac contractility, and intestinal secretion, acting as an agonist for NPY receptors Y1, Y2, and Y5. Expressed ubiquitously, NPY modulates cellular responses by selectively inhibiting forskolin-induced cAMP accumulation in L-M(TK-) cells expressing rat Y1 or Y2 and in HEK293 cells expressing rat Y5, more so than in cells expressing rat Y4 receptors (EC50s = 0.15, 2.7, 0.66, and >1,000 nM, respectively). Additionally, it elevates perfusion pressure in isolated guinea pig hearts (EC30 = 1.3 nM) and, when administered intracerebroventricularly at 300 pmol/animal, it notably increases food intake in rats.

Neuropeptide Y (29-64), amide, human (TFA) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.It is showed that Neuropeptide Y (29-64), amide, human (TFA) is able to protect cortical neurons from Aβ25-35 t

GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003). GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2 References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003).

Acetyl-(D-Arg2)-GRF (1-29) amide (human) acts as a GRF antagonist and inhibits GH secretion, making it useful in endocrine research [1].

Neuropeptide AF (93-110), Human is an endogenous antiopioid peptide.

Neuropeptide W-23 (human) (NPW-23) TFA, representing the active form of Neuropeptide W, functions as an endogenous agonist for both NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1].

Human PTH-(1-31) amide, an analog of PTH, effectively stimulates phosphatidylcholine hydrolysis and promotes the release of adenylyl cyclase [1].

Galanin (1-13)-Neuropeptide Y (25-36) amide exhibits high-affinity binding to galanin receptors, comparable to that of galanin itself [1].

Human PTHrP-(1-34)NH2, also known as PTH-Related Protein (1-34) amide for human, mouse, and rat, is the N-terminal fragment of PTHrP. This peptide induces hypercalcemia and is utilized in the study of humoral hypercalcemia of malignancy [1].

[His1,Nle27] GHRF (1-32), amide, human is a synthetic analog of the growth hormone-releasing hormone (GHRH) with enhanced affinity for the growth hormone-releasing hormone receptor (GHRHR) [1].